Addition of plerixafor for mobilization of stem cells with bortezomib is feasible in dialysis-dependent multiple myeloma. (December 2021)

• Record Type: Journal Article
• Authors: Taenaka, Ryutaro; Takigawa, Ken; Okamura, Kazuhiro; Obara, Teppei; Nishimura, Naoaki; Kohno, Kentaro; Aoki, Kenichi; Ogawa, Ryosuke
• Is Part Of: Transfusion and apheresis science. Volume 60:Number 6(2021)
• Publication Date: 2021-12
• Subjects: Hematopoietic stem cell mobilization -- Multiple myeloma -- Dialysis -- Plerixafor -- Bortezomib; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2021.103279
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: Plerixafor and bortezomib have recently been used in autologous stem cell collection to increase the amount of stem cells collected. However, no reports have described the combined use of plerixafor and bortezomib in cases of dialysis-dependent multiple myeloma. The dialysis-dependent multiple myeloma patient in the present study had a small amount of CD34-positive cells with plerixafor and filgrastim, and also with bortezomib and cyclophosphamide. However, by adding plerixafor to bortezomib and cyclophosphamide, collected CD34-positive cells were increased six-fold compared to the previous day. These findings suggest that the combination of plerixafor and bortezomib may be effective in those patients.